Kevin Koch

Kevin has served as President, Chief Executive Officer, and a board member at Edgewise Therapeutics since 2017. He has also served as a Venture Partner with OrbiMed since 2016.

Kevin has been active in the life sciences industry for 20+ years, with a focus on drug discovery, translational medicine and clinical development. Most recently, Kevin was the Senior Vice President of Drug Discovery: Chemical and Molecular Therapeutics at Biogen, where he managed global drug discovery and biomarker development, as well as the immunology and hematology teams.

From 1998 to 2013, Kevin served as the President, Chief Scientific Officer, Board member, and co-founder of Array BioPharma Inc. While there, he built a fully integrated R&D team that oversaw the invention of over 20 clinical development candidates in multiple therapeutic areas. Prior to Array, Kevin held senior positions at Amgen Inc. and Pfizer Central Research.

Kevin earned a Bachelor of Science in Chemistry and Biochemistry from State University of New York at Stony Brook, and a PhD in Organic Chemistry from the University of Rochester.